The launch of OpenAI GPT-Rosalind on April 17, 2026, marks the end of the traditional patent cliff as a predictable […]
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
The Generic Entry Problem Nobody States Plainly Every branded pharmaceutical product has a clock on it. The moment the FDA
Why the GCC Derails Pharma IP Teams That Know the U.S. System Cold There is a particular category of expensive
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
The Notice That Never Gets Sent Pharmaceutical companies do not issue press releases announcing lifecycle extension campaigns. They do not
Read the Patent Trail: 4 Signals Your Competitor Is Extending a Drug’s Life Read Post »
Executive Summary Most biopharma packaging sales reps knock on the wrong doors at the wrong time. They call on brand-side
On April 16, 2026, OpenAI did something it had never done before: it shipped a model designed not to chat,
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
When Humira lost its final U.S. patent protection in January 2023, more than thirty companies had already committed manufacturing capacity
The Answer Is Not 20 Years Every pharmaceutical patent lawyer knows the frustration. A client asks how long drug patent
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
The pharmaceutical industry has been stuck in a productivity rut for decades. We spend billions of dollars and ten years
Slash drug discovery timelines with GPT-Rosalind Read Post »
Get fresh news and insights, drug patent expirations & more…
